Matsuzaki Y, Honda A
Division of Gastroenterology and Hepatology, Tokyo Medical University, Kasumigaura Hospital, 3-20-1 Ami-Machi-Chuoh, Inashikigun, Ibaraki 300-0395, Japan.
Curr Pharm Des. 2006;12(26):3411-21. doi: 10.2174/138161206778194015.
Dehydroepiandrosterone (DHEA) is the most abundant adrenal androgenic steroid in young adult humans. The physiological functions of DHEA in preventing human carcinogenesis are still controversial, but a lot of reports have shown that pharmacological doses of DHEA show chemopreventive and anti-proliferative effects on tumors in rodents. Although a therapeutic dose of DHEA has been reported to promote hepatocarcinogenesis in rats due to peroxisomal proliferation, it remains unclear whether DHEA is a peroxisome proliferator in human liver. The chemopreventive and anti-proliferative effects of DHEA are not explained by a single mechanism, and at least four mechanisms seem to contribute to these effects: 1) depletion of NADPH and ribose-5-phosphate due to the inhibition of glucose-6-phosphate dehydrogenase activity, 2) suppression of cholesterol biosynthetic pathway by inhibition of HMG-CoA reductase, 3) interference with cell proliferation signaling pathways, and 4) suppression of nitric oxide generation through down-regulation of nitric oxide synthase II. In addition to studies of the mechanisms underlying the anti-neoplastic effects, searches for more potent and less androgenic DHEA derivatives are ongoing. A small amount of DHEA is endogenously metabolized to 7-oxygenated DHEA, and this may represent a metabolic pathway to more potent steroid hormones. Androsterone, epiandrosterone and etiocholanolone have been considered to be merely inactive end products of DHEA, but may in fact be physiological effectors in their own right. In addition, DHEA analogs such as 3beta-methyl-5-androsten-17-one, 16alpha-fluoro-5-androsten-17-one and 16alpha-fluoro-5alpha-androstan-17-one have been synthesized and shown to be more effective inhibitors of tumor growth, compared with DHEA itself. However, to design potent and safe DHEA derivatives, identification of the DHEA receptor and clarification of the mechanisms of DHEA action are required.
脱氢表雄酮(DHEA)是年轻成年人体内含量最丰富的肾上腺雄激素类固醇。DHEA在预防人类癌症发生方面的生理功能仍存在争议,但许多报告表明,药理剂量的DHEA对啮齿动物肿瘤具有化学预防和抗增殖作用。尽管有报道称治疗剂量的DHEA会因过氧化物酶体增殖而促进大鼠肝癌发生,但DHEA在人肝脏中是否为过氧化物酶体增殖剂仍不清楚。DHEA的化学预防和抗增殖作用并非由单一机制解释,至少有四种机制似乎促成了这些作用:1)由于葡萄糖-6-磷酸脱氢酶活性受到抑制,导致NADPH和5-磷酸核糖耗竭;2)通过抑制HMG-CoA还原酶来抑制胆固醇生物合成途径;3)干扰细胞增殖信号通路;4)通过下调一氧化氮合酶II来抑制一氧化氮生成。除了对抗肿瘤作用机制的研究外,人们还在不断寻找更有效且雄激素活性更低的DHEA衍生物。少量的DHEA会内源性代谢为7-氧化DHEA,这可能代表了一条通往更强效类固醇激素的代谢途径。雄酮、表雄酮和本胆烷醇酮一直被认为仅仅是DHEA的无活性终产物,但实际上它们自身可能就是生理效应物。此外,已经合成了DHEA类似物,如3β-甲基-5-雄烯-17-酮、16α-氟-5-雄烯-17-酮和16α-氟-5α-雄甾烷-17-酮,与DHEA本身相比,它们对肿瘤生长的抑制作用更有效。然而,要设计出高效且安全的DHEA衍生物,需要鉴定DHEA受体并阐明DHEA的作用机制。